The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real‐world experience

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|6|838-844

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.6, 2018-03, pp. : 838-844

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 6, 2015-03 ,pp. : 544-563

John Wiley & Sons Inc

Access to resources Recommend Favorite

P152: Real‐world effectiveness of Ledipasvir/Sofosbuvir 8 weeks chronic hepatitis C treatment

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 95-96

John Wiley & Sons Inc

Access to resources Recommend Favorite

Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 33, Iss. 3, 2018-03 ,pp. : 710-717

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 25-30

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection

By  

HEPATOLOGY, Vol. 64, Iss. 4, 2016-10 ,pp. : 1049-1056

John Wiley & Sons Inc

Access to resources Recommend Favorite